Innovation Pharmaceuticals Reports New In Vivo Antifungal Data Showing Brilacidins Potential For Treating Fungal Keratitis

Innovation Pharmaceuticals Reports New In Vivo Antifungal Data Showing Brilacidins Potential For Treating Fungal Keratitis

In addition, brilacidin is being investigated by NIH/NIAID to further characterize its broad-spectrum antifungal activity.

WAKEFIELD, MA, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Via NewMediaWire - Innovation Pharmaceuticals (OTCQB:IPIX) (the "Company"), a clinical-stage biopharmaceutical company, today announced an ongoing study of a broad-spectrum antifungal drug . Brilacidin activity provides an update and defensin is the company's anti-microbial and immunomodulatory candidate.

Previous studies conducted by scientists at the University of São Paulo (USP) in Brazil have shown that brilacidin can potentiate several antifungal drugs on the market, including caspofungin, voriconazole and posaconazole. In addition, brilacidin c. showed strong single-agent activity (MIC=2.5 μM) against neoformans , a deadly fungus that causes about 220,000 cases of cryptococcal meningitis worldwide each year, and for which there is little effective treatment.

New in vivo data from an A. fumigatus fungal keratitis model show that brilcidin reduces fungal burden and disease severity by improving corneal thickness compared to controls. There was almost no viable fungus in corneas treated with brilacid, suggesting that the compound suppresses fungal proliferation in the cornea. Fungal keratitis affects 1.5 million people worldwide each year, 75 percent of whom may lose their eye and/or vision.

This new brilacidin complements previous in vitro results in fungal keratitis and in vivo evaluation of brilacidin as an ocular anti-infective in bacterial keratitis. A broad-spectrum drug that could target both fungal and bacterial keratitis would be uniquely positioned in terms of therapeutic profile and commercial potential.

In this regard, the World Health Organization (WHO) recently published a list of priority fungal pathogens to stimulate research, development and policy interventions to strengthen the global response to fungal infections and antifungal resistance. Based on new in vitro tests, brilacidin c. Neoformans , A. fumigatus , c. shows promising antifungal activity against many of these priority pathogens, including albicans , mucorales , Fusarium , pseudosporium spp. , Lomentospora proficans and C. krusei .

Planned next steps in brilacidin antifungal research include expansion of in vitro and in vivo testing in additional clinical isolates and animal models and publication of scientific results. In collaboration with the NIH/NIAID Division of Mycology, brilacidin will also be studied in different fungal species to further characterize its broad-spectrum antifungal activity. Future updates are planned.

1, 2, 3 regarding antifungal drugs

There are up to 5 million species of fungi on Earth, of which about 100,000 species have been identified. About 300 species of fungi cause disease in humans. In general, Candida , Cryptococcus and Aspergillus represent the main culprits of invasive fungal infections. There is a large unmet medical need for the development of new antifungal agents, particularly with regard to the emergence of resistance in the clinical setting. The usefulness of current antifungal treatments is limited by concerns about toxicity, fungal and non-fungal properties, and drug interactions. In the United States, antifungal drugs may qualify for accelerated clinical development under the Infectious Disease Qualified Product, Orphan Drug, and Population Limited Pathway Development programs. Large clinical trials of antifungal drugs, requiring 300-600 patients, are generally smaller than in other areas of infectious diseases. Caspofungin sales are estimated at $414 million in 2021, the global antifungal drug market is estimated at $14.8 billion in 2021 and will reach $20.5 billion by 2030.

1 Current antifungal agents, new perspectives for antifungal therapy and future approaches

2 Global Casfungin Market Research Report 2022 (Status and Outlook)

3 Antifungal drug market size estimated to reach $20.5 billion by 2030; Grand View Research, Inc.

WARNING!

Subscriptions to the Innovation Pharmaceuticals e-newsletter are available at:

http://www.ipharminc.com/email-alerts/

About Pharmaceutical Innovation

Innovation Pharmaceuticals Inc. (IPIX) is a clinical-stage biopharmaceutical company developing a portfolio of innovative therapies targeting multiple areas of unmet medical need, including inflammatory diseases, cancer and infectious diseases. The company is actively evaluating other potential investment opportunities that could add value and diversify its portfolio.

Forward-looking statements. This press release contains forward-looking statements made pursuant to the protective provisions of the Securities and Exchange Reform Act of 1995, including, but not limited to, statements regarding future product development plans, including certain instructions. ; statements regarding the therapeutic potential and capabilities of the StingRay System; future regulatory developments; and all other statements that are not statements of historical fact. These statements involve risks, uncertainties and assumptions that could cause actual results and experience to differ materially from the projected results and expectations expressed in these forward-looking statements. The Company has, in some cases, identified forward-looking statements with words such as "estimate," "believe," "hope," "estimate," "anticipate," "anticipate," "plan," "aim," "goal." " " ", "possible", "may", "suggested" and similar expressions. Other factors that could cause actual results to differ materially from those anticipated in forward-looking statements include risks associated with conducting preclinical and clinical studies and obtaining regulatory and patent approvals in the United States and other jurisdictions, including , but not limited to; the compound and devices have not successfully completed preclinical or clinical trials or received regulatory approval for sale and marketing in the United States or elsewhere; The results of the previous test cannot be repeated in future exams and tests; substantial capital requirements and future availability to fund the Company's operations and research and development, including the amount and timing of sales of common stock under stock purchase agreements; and the Company's licensees do not successfully complete preclinical or clinical trials and the Company does not receive milestone payments. A more complete description of these and other risk factors is included in the company's filings with the Securities and Exchange Commission. Many of these risks, uncertainties and assumptions are beyond the company's ability to control or predict. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only to information currently available to the Company at the time they are made, and the Company does not undertake to publicly disclose the results of any revisions that may be made to reflect such forward-looking statements. or reflect unforeseeable events, except as required by law or regulation or circumstances in effect after the date of this press release.

Investor and media communications
Innovation Pharmaceuticals Inc.
Leo is honest
info@ipharminc.com

President Trump and members of the coronavirus task force meet with pharmaceutical executives